Abstract
Non small cell lung cancer is one of the leading causes of death in the industrial countries and some 70% of patients have non surgically eradicable disease. Platinum based combined regimens can achieve 35-40% objective responses, but advanced age, low performance status and concurrent diseases can exclude up to 60% of patients from an adequate poliychemotherapy treatment.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Aged
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Remission Induction
-
Survival Analysis
-
Treatment Outcome
-
Vinblastine / adverse effects
-
Vinblastine / analogs & derivatives*
-
Vinblastine / therapeutic use
-
Vinorelbine